Clinical Trials Browser

Phase 2 × INDUSTRY × Afatinib × Clear all

NCT05588609 2025-09-18

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Phase 2 Terminated

GenitourinaryThoracic

NSCLC Harboring NRG1 Fusion

NCT02597946 2025-02-19

Afatinib in NSCLC With HER2 Mutation

Phase 2 Completed

18 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT00748709 2025-02-11

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Phase 2 Terminated

20 enrolled 11 charts

Neoplasms

NCT02780687 2020-11-18

LUX-Bladder 1

Phase 2 Completed

42 enrolled 16 charts

Urologic Neoplasms

NCT01466660 2020-04-07

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Phase 2 Completed

319 enrolled 19 charts

Lung Neoplasms

NCT00801294 2017-12-29

A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT00525148 2016-09-16

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Phase 2 Completed

129 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT00514943 2016-07-26

BIBW 2992 (Afatinib) in Head & Neck Cancer

Phase 2 Completed

124 enrolled 31 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT01441596 2015-09-07

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Phase 2 Completed

121 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00706628 2015-01-15

A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer

Phase 2 Completed

87 enrolled 20 charts

Prostatic Neoplasms

NCT00711594 2015-01-15

LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Phase 2 Completed

74 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT00425854 2013-12-31

An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer

Phase 2 Completed

50 enrolled 13 charts

Breast Neoplasms

NCT00826267 2013-12-31

6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

Phase 2 Completed

29 enrolled 9 charts

Breast Neoplasms

NCT01003899 2013-12-31

A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]

Phase 2 Completed

43 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT00708214 2013-12-30

BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer

Phase 2 Completed

28 enrolled 20 charts

Breast Neoplasms

NCT00875433 2013-12-30

Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours

Phase 2 Completed

60 enrolled 26 charts

Neoplasms